Taysha Gene Therapies, Inc. (TSHA)
6.015
-0.18
(-2.98%)
USD |
NASDAQ |
Aug 26, 16:00
6.14
+0.12
(+2.08%)
After-Hours: 20:00
Taysha Gene Therapies Total Liabilities (Quarterly) : 83.17M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.17M |
| March 31, 2026 | 88.41M |
| December 31, 2025 | 236.79M |
| September 30, 2025 | 97.56M |
| June 30, 2025 | 84.60M |
| March 31, 2025 | 83.30M |
| December 31, 2024 | 204.88M |
| September 30, 2024 | 91.42M |
| June 30, 2024 | 91.52M |
| March 31, 2024 | 99.15M |
| December 31, 2023 | 192.06M |
| September 30, 2023 | 244.88M |
| June 30, 2023 | 118.66M |
| Date | Value |
|---|---|
| March 31, 2023 | 116.55M |
| December 31, 2022 | 127.68M |
| September 30, 2022 | 100.34M |
| June 30, 2022 | 109.62M |
| March 31, 2022 | 115.25M |
| December 31, 2021 | 118.57M |
| September 30, 2021 | 100.65M |
| June 30, 2021 | 55.36M |
| March 31, 2021 | 19.96M |
| December 31, 2020 | 7.579M |
| September 30, 2020 | 11.62M |
| June 30, 2020 | 20.09M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Altimmune, Inc. | 53.00M |
| Protalix Biotherapeutics, Inc. | 38.93M |
| Humacyte, Inc. | 106.83M |
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 470.43M |
| Shareholders Equity (Quarterly) | 387.27M |
| Debt to Equity Ratio | 0.1469 |
| Current Ratio | 17.76 |
| Net Debt Paydown Yield | 0.05% |